ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 535

Is There Achilles Tendon Damage in Rheumatoid Arthritis Patients?

Marina Natalia Fornaro1, Tomas Cazenave2, Maria Celeste Orozco3, María Victoria Martire4, Estela Reyes2, Haydee Schmulevich2, Gustavo Citera5 and Marcos G. Rosemffet3, 1Section of Rheumatology, Instituto de Rehabilitación Psicofísica, buenos aires, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Instituto Médico Platense, La Plata, Argentina, 5Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Ankle involvement is common in Rheumatoid Arthritis (RA). It has been reported that more than 90 % of patients develop ankle symptoms over the course of the disease. In spite of this, it remains a neglected anatomical area since clinical implications of ankle involvement appear to be continuously underestimated. We analized the ultrasound (US) features of the Achilles Tendon (AT) and enthesis in patients with RA and compared these to healthy athletes. Relations between these findings and clinical and physical therapy parameters were identified.

Methods: Consecutive patients aged ≥18 with RA according to ACR/EULAR 2010 criteria were included. We consigned socio-demographic data, disease duration, physical activity and Body Mass Index (BMI). Clinical evaluation relied on the Disease Activity Score 28 (DAS28), Health Assessment Questionnaire (HAQ), Routine Assessment of Patient Index Data 3 (RAPID 3), as well as on a visual analog scale (VAS), and entheseal pain. Separately, AT thickness and echogenicity were examined bilaterally with US in 60 ankle regions. US examinations were performed by two experienced rheumatologists. To evaluate AT involvement, we used the Madrid Sonographic Enthesitis Index (MASEI) evaluating elementary lesions: bursitis, calcification, erosion, Power Doppler (PD), thickening of tendon, and structural change. Statistical analysis: Standard descriptive results were expressed as the mean ± standard deviation (SD). Chi-square Test and Fisher’s exact test were used for categorical variables whereas T test for the continuous variables.

Results: A total of 60 ankles from 30 patients with RA and 36 ankles from 18 healthy controls were assessed. The mean (±SD) age was 58.3 ± 9.5 years and disease duration were 14.5 ± 5.9 years in RA patients. 30% of patients with RA had foot and ankle pain at visit. The mean (±SD) DAS28, HAQ and RAPID3 were 3.46 ± 0.9, 0.9 ± 0.6, and 11 ± 6.5 respectively. 26.7% were obese. 30% of RA patients performed physical activity. At least 1 AT lesion was found in US of all RA patients. The most frequent US abnormality in RA patients was tibialis posterior tenosynovitis followed by peroneus longus tenosynovitis. A statistically significant difference was found between RA patients and healthy controls in mean (±SD) MASEI (3.56 ± 2.4 vs. 2.33 ± 1.7, p=0.01), and subitem scores such as: structural changes (0.66 ± 0.4 vs. 0.2 ± 0.4, p=<0.01), erosion (0.8 ± 1.3 vs. 0.02 ± 0.16, p=<0,01) and PD (0.3 ± 0.9 vs. 0.02 ± 0.16, p=0.03).

Conclusion: Achilles tendon involvement is rather frequent in RA patients. The MASEI score was significantly higher in patients with RA compared with athletes.


Disclosure: M. N. Fornaro, None; T. Cazenave, None; M. C. Orozco, None; M. V. Martire, None; E. Reyes, None; H. Schmulevich, None; G. Citera, Novartis, Pfizer Inc, 2,AbbVie, Bristol-Myers Squibb, Eli Lilly, Genzyme, Novartis, Pfizer Inc, Roche, 5; M. G. Rosemffet, None.

To cite this abstract in AMA style:

Fornaro MN, Cazenave T, Orozco MC, Martire MV, Reyes E, Schmulevich H, Citera G, Rosemffet MG. Is There Achilles Tendon Damage in Rheumatoid Arthritis Patients? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/is-there-achilles-tendon-damage-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-there-achilles-tendon-damage-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology